

**LISTING OF THE CLAIMS**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) A method of treating functional constipation or C-IBS, in a warm-blooded animal in need of such treatment, which method comprises administering to said animal an effective amount of an IBAT inhibitor selected from:  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((R)-1-carboxy-2-methylthio-ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxybutyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-(R)-hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-(2-sulphoethyl)carbamoyl)-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((R)-1-carboxy-2-methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoylbenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-[N-((S)-2-hydroxy-1-carboxyethyl)carbamoyl]propyl}carbamoylbenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;  
or a pharmaceutically acceptable salt, solvate, solvate of such a salt, or an *in vivo* hydrolysable ester formed on an available carboxy or hydroxy or an *in vivo* hydrolysable amide formed on an available carboxy thereof.

5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Previously Presented) The method according to claim 4 or claim 10 for the treatment of functional constipation.
9. (Previously Presented) The method according to claim 4 or claim 10 for the treatment of C-IBS.
10. (Currently Amended) A method of treating functional constipation or C-IBS, in a warm-blooded animal in need of such treatment, which method comprises administering to said animal an effective amount of an IBAT inhibitor selected from:  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-  
(carboxymethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-  
(carboxymethyl)carbamoyl]4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-  
1,5-benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(2-  
sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)-1'-phenyl-1'-[N'-(2-  
sulphoethyl)carbamoyl]methyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-sulphoethyl)carbamoyl]-  
4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-  
sulphoethyl)carbamoyl]4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-  
carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-  
carboxyethyl)carbamoyl]4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(5-  
carboxypentyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-  
carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-  
benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N- $\alpha$ -[N'-(2-sulphoethyl)carbamoyl]-2-  
fluorobenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-5-ethyl-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(R)-1-[N''-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(R)-(2-hydroxy-1-carboxyethyl)carbamoyl]benzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(R)-2-hydroxy-1-(carboxymethyl)carbamoyl]benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-[(R)- $\alpha$ -{N'-{(R)-1-[N''(R)(2-hydroxy-1-carboxyethyl)carbamoyl]2-hydroxyethyl}carbamoyl}benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\alpha$ -[N'-{carboxymethyl}carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N- $\alpha$ -[N'-{ethoxy(methyl)phosphorylmethyl}carbamoyl]benzyl)carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-[(R)- $\alpha$ -{N'-{2-[(hydroxy)(methyl)phosphoryl]ethyl}carbamoyl}benzyl]carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-methylthio-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[(R)- $\alpha$ -{N'-{2-[(methyl)(ethyl)phosphoryl]ethyl}carbamoyl}-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-{N-[(R)- $\alpha$ -(N'-{2-[(methyl)(hydroxy)phosphoryl]ethyl}carbamoyl)-4-hydroxybenzyl]carbamoylmethoxy}-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[(R)-N'-(2-methylsulphinyl-1-carboxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methoxy-8-[N-{(R)- $\alpha$ -[N'-(2-sulphoethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-(S)-3-(R)-4-(R)-5-(R)-2,3,4,5,6-pentahydroxyhexyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(S)-1-carbamoyl-2-hydroxyethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(hydroxycarbomoyl-methyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -{N'[2-(N'-pyrimidin-2-ylureido)ethyl]carbamoyl}benzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -{N'[2-(N'-pyridin-2-ylureido)ethyl]carbamoyl}benzyl}carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(1-3-butoxycarbonylpiperidin-4-ylmethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;

1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2,3-dihydroxypropyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-[N-((R)- $\alpha$ -(N'-(2-(3,4-dihydroxyphenyl)-2-methoxyethyl) carbamoyl)benzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8(N-{(R)- $\alpha$ -[N-(2-aminoethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(piperidin-4-ylmethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine; and  
1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-(N-{(R)- $\alpha$ -[N'-(2-N,N-dimethylaminosulphamoylethyl)carbamoyl]benzyl} carbamoylmethoxy)-2,3,4,5-tetrahydro-1,5-benzothiazepine;  
or a pharmaceutically acceptable salt, solvate, solvate of such a salt, or an *in vivo* hydrolysable ester formed on an available carboxy or hydroxyl or an *in vivo* hydrolysable amide formed on an available carboxy thereof.